Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

On August 31, 2026 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, reported that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mor and Dr. Reg Seeto, Chief Executive Officer of Scipher Medicine Corporation (Scipher), will be attending the H.C. Wainwright Conference in New York City in person and will be co-hosting 1×1 investor meetings September 14-16, 2026. On July 8, 2026 Chemomab and Scipher announced a definitive merger agreement, which is expected to close before year-end. Based on its pioneering work in immunology precision medicine, Scipher plans to advance Chemomab’s first-in-class anti-CCL24 antibody nebokitug into a Phase 2 trial in rheumatoid arthritis, a $24 billion market opportunity with substantial unmet need.

Chemomab Presentation at H.C. Wainwright 28th Annual Global Investment Conference
Date: September 11, 2026
Time: Available starting at 7:00 am ET for 90 days
Format: Prerecorded webcast presentation
Webcast Link: View Source

For information on attending the 2026 H.C. Wainwright Global Investment Conference, contact your representative or click here.

(Press release, Chemomab, AUG 31, 2026, View Source [SID1234670441])